Beleggen.nl
Uitgebreid zoeken
Markt MonitorMarkt Monitor

BioPharma Terug naar discussie overzicht

Mooi instap moment Dendreon

1.743 Posts
Pagina: «« 1 ... 38 39 40 41 42 ... 88 »» | Laatste | Omlaag ↓
  2. [verwijderd] 3 april 2007 11:16

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    hoi allen,

    even een vraag....
    Het schijnt dat er al een middel op de markt is(zie link.
    Het heet "Taxotere"
    Heeft iemand hier een idee over hoe het product werkt,dus bijwerkingen enzv.

    Lijkt me wel interresant om de vergelijking te maken met het product van DNDN.

    Alvast bedankt

    Pasam

    messages.finance.yahoo.com/Stocks_%28...

    (zie regel 2)
  3. [verwijderd] 3 april 2007 11:21

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    pasam schreef:

    hoi allen,

    even een vraag....
    Het schijnt dat er al een middel op de markt is(zie link.
    Het heet "Taxotere"
    Heeft iemand hier een idee over hoe het product werkt,dus bijwerkingen enzv.

    Lijkt me wel interresant om de vergelijking te maken met het product van DNDN.

    Alvast bedankt

    Pasam

    messages.finance.yahoo.com/Stocks_%28...

    (zie regel 2)
    taxotere=chemo

    provenge=weinig bijwerkingen
    veel mensen willen geen chemo

    wanneer ze wel chemo willen dan goede combitherapie
  5. jip banaan! 3 april 2007 12:26

    • jip banaan!

      Lid sinds: 10 feb 2005

      Laatste bezoek: 22 feb 2024

    • Aanbevelingen

      Ontvangen: 2697

      Gegeven: 9726

    •    Aantal posts: 13.304

    quote:

    rac69 schreef:

    [quote=jip banaan!]
    [quote=rac69]
    kost voortaan 2,50 per maand.

    je kunt het via instellingen weer activeren.
    [/quote]
    grapje??
    [/quote]

    kom net thuis koers doet het leuk trouwens,maarre is geen grapje heb gebeld met binck en het is echt zo.
    als je alleen nasdaq wil zien kost dat 2,50 maar wil je de rest amex enz voort zien betaal je meer.wil je nasdaq en amex en dow zien moet je per divisie 2,50 betalen.
    schandalig,als ze daar nou ook een diepte boekje bj gaven ok maar zo,nee.
    heb het gisteren geactiveerd, die paar knaken maakt niet uit, ik wil voor een goed diepteboekje ook wel betalen, zou het handig vinden als binck dat had.
  7. [verwijderd] 3 april 2007 16:01

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    pasam schreef:

    hoi allen,

    even een vraag....
    Het schijnt dat er al een middel op de markt is(zie link.
    Het heet "Taxotere"
    Heeft iemand hier een idee over hoe het product werkt,dus bijwerkingen enzv.

    Lijkt me wel interresant om de vergelijking te maken met het product van DNDN.

    Alvast bedankt

    Pasam

    messages.finance.yahoo.com/Stocks_%28...

    (zie regel 2)
    Provenge (DNDN) = + 4,5 maanden met amper bijwerkingen
    Taxotere= + 2,5 maanden met veel bijwerkingen
    Het schijnt dat Taxotere + Provenge samen nog een veelvoud van de verlenging van beide middelen alleen geeft.

    P.

    + 4% = 58 cents
  13. [verwijderd] 4 april 2007 12:54

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Dendreon Corporation: The Next Biotech Winner
    Dendreon Corporation: The Next Biotech Winner
    Posted on Apr 4th, 2007 with stocks: DNDN

    Hillel Shakked submits: Many have noticed Friday's remarkable price movement in Dendreon Corporation (DNDN) and are wondering what the upside from here is. In the report below, I will run a back-of-an-envelope analysis for DNDN's current evaluation and will discuss its longer term potential.

    Let me start with a basic valuation model:

    Leading therapeutic vaccine candidate, Provenge, is currently being evaluated by the FDA for AIPC (androgen-independent prostate cancer), the terminal stage of the disease also known as hormone-independent prostate cancer [HRPC]. Patients diagnosed with AIPC typically have a 16 to 18 month life expectancy.
    Market size: ~150,000 current prevalence, with 50,000 newly diagnosed patients every year (US only)
    Treatment cost: est. $15,000-$20,000 per infusion - 3 infusions are needed for the treatment, administered two weeks apart; cost not specified yet
    Competition: Taxotere, a very strong chemotherapy drug, is the only drug approved by the FDA for AIPC that has a proven survival benefit. Over 50% of asymptomatic (without bone pain) AIPC patients prefer NOT to use Taxotere due to its relatively severe side effects. Note that in its pivotal clinical trial, Taxotere showed a median survival [MS] benefit of 3.2 months in the asymptomatic subgroup (in comparison to Provenge's 4.5 month MS benefit).
    Market potential – I'll be conservative to assume 65% penetration rate and a cost of $45,000 per patient (in line with the modern cancer biologics - Avastin, Herceptin, Erbitux etc). Which doctor will not recommend that his patient try a drug that has a markedly less severe side effect profile than Taxotere and that has shown a greater MS benefit in both of its Phase 3 trials?
    As evidenced by the prostate cancer patient advocacy groups at the March 29 Cellular, Tissue, & Gene Therapy Advisory Committee as well as by physicians interviewed on every media outlet in the recent days, the demand for Provenge seems to be very high right off the bat, so assuming a 65% penetration rate 3 years after approval could be a fair assumption here.

    Peak revenues (US market): 65% x 50,000 * $45,000 = $1.462 billion

    Discount the peak revenue by 12.5% per year for 3 years and one arrives at $1.0 billion.

    Biotechs with promising pipelines typically trade at 7 to 20 price/sales, so by taking the low end of the above range we can conservatively assume that after Provenge's approval, the price per share of Dendreon will eventually reflect a market cap of at least $7 billion.

    DNDN has 82 million shares outstanding, ~$100 million in cash as of 3/31, and can sell up to $200 million worth of its common stock on its current shelf. Assuming another dilution round (possibly as part of a RoW partnership deal), another 10-15 million shares could then be added to the float for a total of around 100 million shares.

    Hence, a price per share of $70 within several months post approval is not out of the question.

    Based on its current price per share of around $13, one could easily argue that DNDN's share price is very undervalued, considering that Provenge is highly likely to be approved by May 15. The FDA usually follows the recommendation of its Advisory Committees, and especially so when the indication is a terminal one and the advisory panel has recommended that the therapy is both safe and substantially effective. Thursday’s CTGTAC voted 17 to 0 that Provenge was safe and 13 to 4 that it showed substantial evidence of efficacy.

    The efficacy vote came with a great deal of excitement because the efficacy question, as originally written in the FDA's briefing documents, was unusually stringent and did not follow FDA guidelines. The question originally worded by the FDA was “Did the treatment establish efficacy?” When the term “establish” was interpreted and vocalized by the first three advisory panel members to mean “100% conclusiveness,” the committee chairman, Dr. James Mule, halted the voting and asked the FDA attendees if the question was worded properly, noting that “substantial efficacy” is the language in the FDA’s own guidelines for drug approvals. The two high-ranking FDA officials attending the meeting agreed with Dr. Mule and corrected the overly stringent terminology. The revised question was re-asked, “Does the product demonstrate substantial evidence of efficacy?” The first three panel members immediately reversed their votes, and the final panel vote on efficacy was 13 Yes and 4 No.

    More to Follow

    The price per share calculation above was based only on revenues in the US market. Provenge sales from the rest of the world [ROW] could eventually match US revenues. DNDN has stated that it would like to partner Provenge with a larger biopharma company. Signing a lucrative ROW partnership agreement with a healthy upfront payment and sales milestones, in addition to 20-25% royalties is certainly conceivable post-US approval. Hence, another 25% pop in the pps can be expected when a ROW is announced.

    ADPC (androgen-dependent prostate cancer) indication: The market size of this earlier stage of advanced prostate cancer comprising patients who are still responding to androgen blockers is estimated at two to three times larger than the AIPC market. In mid-2005, Dendreon completed enrollment in a Phase 3 clinical trial that randomized patients to the treatment arm of Provenge plus Lupron or to the control arm of Lupron plus sham Provenge (saline solution). Final data is still years away, but initial results from the earliest enrolled patients have so far shown that Provenge appears to be delaying the rise in PSA from the 0.0 level to the 3.0 level.

    Neuvenge, etc: Dendreon was forced to suspend its follow-on immunotherapy drug, Neuvenge, for breast and ovarian cancer patients who are HER2/Neu positive, in order to conserve its cash. The relentless short selling of DNDN shares blocked the ability of the company to raise enough money without significant dilution. The Neuvenge Phase 2 results showed excellent promise, so it is hoped that this program can be restarted shortly after approval, three years after its suspension.

    21st Century Medicine

    By approving Provenge (PDUFA date is May 15), the FDA jumpstarts cancer therapy into the 21st Century—this is a personalized treatment called autologous immunotherapy—using the patient’s own cells and it is based on Dendreon's patented Antigen Delivery Cassette platform. It is important to note that Dendreon holds numerous patents, as well as exclusive and nonexclusive licenses to use over 20 other antigens for future therapeutic vaccine development. In other words, once DNDN scientists find the most appropriate antigen target expressed in any type of cancer, the same procedure used in administering Provenge immunotherapy can be applied.

    What are the odds of approval? Based on the Advisory Committee [AC] vote of 13 to 4, the odds seem to be quite high. Moreover, surveying the outcomes of the recent FDA Advisory Committees, the FDA has approved 37 of the last 38 treatments following a positive recommendation from an Advisory Committee. The current FDA commissioner is a urological oncologist and prostate cancer survivor whose father passed away from AIPC, who has publicly stated more than once that FDA will serve as a “bridge” to
  15. [verwijderd] 4 april 2007 17:52

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    pasam schreef:

    biotech.seekingalpha.com/article/31496

    biotech.seekingalpha.com/article/31501

    pasam
    Beste P,C
    ben uit DNDN gestapt op 15$ , grote positie weer in ENCY en GNVC, PS psycho , vandaag ook BIOMIRA gekocht, nog zeer goedkoop indien DNDN in mei word goedgekeurd dan is op deze niveau's kopen van BIOMIRA een buitenkans!!
    gr leg
  18. [verwijderd] 4 april 2007 21:10

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    hij gaat nog steeds lekker psycho.
    mooi om te zien elke dag dat gevecht.
    volgende week staan we aanzienlijk hoger dan waar we nu staan.

    mama gaat er ook weer vandoor zie ik.
    en goed er van door.
  19. [verwijderd] 4 april 2007 21:15

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    rac69 schreef:

    mama gaat er ook weer vandoor zie ik.

    Ach jongen, ben je nu helemaal alleen thuisgelaten?

    Bel maar gauw 0800-0432 als je je angstig en eenzaam, verlaten en ontheemd voelt.

    Psycho
  20. [verwijderd] 4 april 2007 21:19

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    psycho-pharma schreef:

    [quote=rac69]
    mama gaat er ook weer vandoor zie ik.

    [/quote]

    Ach jongen, ben je nu helemaal alleen thuisgelaten?

    Bel maar gauw 0800-0432 als je je angstig en eenzaam, verlaten en ontheemd voelt.

    Psycho
    hahahahahahaha

    psycho,altijd scherp.
    mooi.
  21. [verwijderd] 4 april 2007 21:36

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Briefing.com just reported.

    14:57 DNDN Dendreon: Hearing jagnotes reporting a rumor that DNDN will announce an investment and licensing agreement with a Major U.S. drug company.

    www.jagnotes.com/frontpage.cfm?attemp...

    Burp. Het betere jat-, knip- en plakwerk. Voor wat het waard is.
1.743 Posts
Pagina: «« 1 ... 38 39 40 41 42 ... 88 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beleggen.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.018
AB InBev 2 5.501
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.679
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 265
Accsys Technologies 23 10.703
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 189
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.752
Aedifica 3 916
Aegon 3.258 322.852
AFC Ajax 538 7.088
Affimed NV 2 6.297
ageas 5.844 109.893
Agfa-Gevaert 14 2.050
Ahold 3.538 74.339
Air France - KLM 1.025 35.047
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.041
Alfen 16 24.859
Allfunds Group 4 1.473
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.822
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.250
AMG 971 133.366
AMS 3 73
Amsterdam Commodities 305 6.690
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 15.007
Apollo Alternative Assets 1 17
Apple 5 382
Arcadis 252 8.778
Arcelor Mittal 2.033 320.714
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.302
Aroundtown SA 1 219
Arrowhead Research 5 9.740
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.139
ASML 1.766 107.458
ASR Nederland 21 4.486
ATAI Life Sciences 1 7
Atenor Group 1 491
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.674
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.392